LAUSR

nfection with SARS-CoV-2, the cause of coronavirus infecious disease–19 (COVID-19), has caused a pandemic after rst being reported in Wuhan, China in December 2019.1 An ver-representation of patients with cancer has been seen n the COVID-19 cohort in the Chinese National Database epository.2 Patients with cancer have been reported to have OVID-19-related case fatality rates of approximately 5–6%,1 nd a 3 to 5-fold higher risk of severe COVID-19, compared to he general population.2 Moreover, patients with hematologcal malignancies and COVID-19 have been reported to have ase fatality rates of up to 37%.3 Another study delineated igher mortality in hospitalized patients with hematological ancers who developed COVID-19 than in hospitalized healthare providers with COVID-19.4 Severe and prolonged immunosuppression is a corollary f treatment for acute lymphocytic leukemia (ALL), which eightens the risk of complications associated with COVID-